Eckels D D, Geiger M J, Sell T W, Gorski J A
Immunogenetics Research Section, Blood Center of Southeastern Wisconsin, Milwaukee 53233.
Hum Immunol. 1990 Mar;27(3):240-53. doi: 10.1016/0198-8859(90)90054-s.
Alloreactive T-cell clones were derived by limiting dilution following priming to allogeneic cells bearing HLA-DR1 alloantigens. Clonal specificities were determined by extensive testing on a panel of allogeneic lymphoblastoid cell lines and by blocking studies with monoclonal antibodies specific for HLA-DR, -DQ, and -DP class II molecules. Out of nine DR1-positive cell lines, three failed to stimulate a subset of the T-cell clones in conventional proliferation assays. Proliferation by all of the clones was blocked by anti-DR antibodies, not by anti-DQ or anti-DP, which was consistent with the conclusion that the HLA-DR molecule was recognized. This DR1-associated polymorphism has been identified as Dw20 by the Tenth International Histocompatibility Workshop. The molecular basis for this altered recognition of the DR1 molecule was determined by allele-specific oligonucleotide hybridization and by DNA sequencing studies. The first, second, and third hypervariable regions of all nine DR1-positive cell lines were identical. Valine and glycine were found at positions 85 and 86 of the DR1 beta 1 chain in DR1 molecules from six of the nine lymphoblastoid cell lines, whereas alanine and valine were found in the three variant (Dw20) DR1-positive cells. By analogy with class I structure, residues 85 and 86 would be located at the extreme C-terminal end of the beta-chain alpha helix. Together or separately, these amino acid differences may define a T-cell recognition element on the DR1 molecule serving to contact allospecific T-cell receptors. Alternatively, if allorecognition involves recognition of a self peptide complexed with an allogeneic MHC molecule, then it is possible that the differences T cells recognize on DR1 class II proteins arise from peptide-specific interactions with residues 85 and 86.
同种反应性T细胞克隆是在对携带HLA - DR1同种异体抗原的同种异体细胞进行致敏后,通过有限稀释法获得的。克隆特异性通过对一组同种异体淋巴母细胞系进行广泛检测以及用针对HLA - DR、- DQ和 - DP II类分子的单克隆抗体进行阻断研究来确定。在九个DR1阳性细胞系中,有三个在传统增殖试验中未能刺激T细胞克隆的一个亚群。所有克隆的增殖都被抗DR抗体阻断,而不是被抗DQ或抗DP抗体阻断,这与HLA - DR分子被识别的结论一致。这种与DR1相关的多态性已被第十届国际组织相容性研讨会鉴定为Dw20。通过等位基因特异性寡核苷酸杂交和DNA测序研究确定了对DR1分子这种改变的识别的分子基础。所有九个DR1阳性细胞系的第一、第二和第三高变区是相同的。在九个淋巴母细胞系中的六个的DR1分子的DR1β1链的第85和86位发现缬氨酸和甘氨酸,而在三个变异(Dw20)DR1阳性细胞中发现丙氨酸和缬氨酸。与I类结构类似,第85和86位残基将位于β链α螺旋的最末端C端。这些氨基酸差异一起或分别可能定义了DR1分子上一个用于接触同种特异性T细胞受体的T细胞识别元件。或者,如果同种识别涉及识别与同种异体MHC分子复合的自身肽,那么T细胞在DR1 II类蛋白上识别的差异可能源于与第85和86位残基的肽特异性相互作用。